Nevertheless, more multicentric trials are needed to confirm these findings to precisely define the indications and timing of PET imaging with FAP-targeting radiopharmaceuticals in GC patients (especially when compared to current reference imaging examinations), and to establish specific clinical recommendations. The gene discussed is FAP; the disease is gastric cancer.